Helicobacter Infections

The cause is infection with organisms of the genus Helicobacter, most notably Helicobacter pylori. The supplied material also links H. pylori virulence factors to persistence in the gastric mucosa and to downstream inflammatory and carcinogenic effects.

H. pylori colonizes the gastric mucosa and persists by using virulence factors that support invasion, survival, and evasion of host defenses. The infection drives chronic inflammation in the gastric microenvironment and is associated with progression from gastritis to peptic ulcer disease and, in some settings, precancerous gastric lesions and gastric cancer. Literature also highlights interactions with the gastric microbiota as part of disease progression.

Persistent Helicobacter pylori gastritis is associated with higher risk of gastric adenocarcinoma in the setting of chronic atrophic gastritis or intestinal metaplasia. A family history of gastric cancer, incomplete intestinal metaplasia, and persistent H. pylori gastritis are specifically mentioned as factors relevant to surveillance decisions. The supplied grounding does not support additional risk factors.

Management is centered on diagnosis, risk stratification, and eradication-oriented therapy for Helicobacter pylori infection. For patients with chronic atrophic gastritis or intestinal metaplasia, high-definition endoscopy with chromoendoscopy and guided biopsies is used to stage disease and detect neoplasia, with surveillance considered in selected higher-risk settings. The grounding supports treatment at the modality level but does not provide specific drug classes for eradication.